Tricyclic compound

US7160894B2 · kind B2 · utility

Assignee

• Asahi Kasei Pharma Corporation · JP

Inventors

• Rintaro Yamada · Tokyo, JP
• Minoru Seto · Tokyo, JP

Key dates

• Filing date: Jun 3, 2004
• Grant date: Jan 9, 2007
• Expiry date: Jun 3, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel compound represented by the formula (1):[R1 represents hydrogen atom, chlorine atom, or hydroxyl group; X1 . . . X2 represents—CH(R2)—CH(R3)—, —CH(R2)—CH(R3)—CH(R4)—, etc.; R2 to R4represent hydrogen atom, or an alkyl group; A1, A11, A2, and A21 represent hydrogen atom, or an alkyl group; Y represents —CH(A3)—, —CH(A3)—C(A4)(A41)—, —CH(A3)—C(A4)(A41)—C(A5)(A51)—, or a single bond; A3, A4, A41, A5, and A51 represent hydrogen atom, or an alkyl group; Z represents hydroxyl group, or —N(A6)(A61); A6 represents hydrogen atom, or an alkyl group, A61 represents hydrogen atom, an alkyl group, an aralkyl group, etc.; and groups in each of one or more combinations selected from the group consisting of combinations of A6 and A3, A6 and A4, A6 and A1, A6 and A2, A2 and A3, A2 and A4, A6 and A5, A3 and A1, and A5 and A1 may bind to each other to form a 5- or 6-membered ring], or a salt thereof, which potently inhibits the phosphorylation of myosin regulatory light chain.